P. Urbas

1.1k total citations · 1 hit paper
12 papers, 814 citations indexed

About

P. Urbas is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, P. Urbas has authored 12 papers receiving a total of 814 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Molecular Biology and 4 papers in Hematology. Recurrent topics in P. Urbas's work include Immunotherapy and Immune Responses (4 papers), Multiple Myeloma Research and Treatments (4 papers) and CAR-T cell therapy research (3 papers). P. Urbas is often cited by papers focused on Immunotherapy and Immune Responses (4 papers), Multiple Myeloma Research and Treatments (4 papers) and CAR-T cell therapy research (3 papers). P. Urbas collaborates with scholars based in United States and Germany. P. Urbas's co-authors include Ronald C. DeConti, Adil Daud, Stephanie Andrews, Vernon K. Sondak, Adam I. Riker, Pamela N. Münster, Daniel M. Sullivan, Jane L. Messina, Kenneth E. Ugen and Richard Heller and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

P. Urbas

12 papers receiving 796 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma

2008 503 citations Adil Daud, Ronald C. DeConti et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
P. Urbas United States	9	386	319	308	267	225	12	814
Urška Kamenšek Slovenia	17	557 1.4×	370 1.2×	243 0.8×	135 0.5×	252 1.1×	52	841
Dongping Wei China	21	164 0.4×	870 2.7×	74 0.2×	472 1.8×	137 0.6×	33	1.2k
S. Annie Gai United States	7	102 0.3×	455 1.4×	475 1.5×	313 1.2×	229 1.0×	9	931
Emily H. Hall United States	13	141 0.4×	265 0.8×	147 0.5×	110 0.4×	74 0.3×	18	519
Melissa Wassink Netherlands	13	70 0.2×	453 1.4×	435 1.4×	184 0.7×	110 0.5×	16	828
Pauliina Lehtolainen Finland	13	99 0.3×	655 2.1×	87 0.3×	232 0.9×	93 0.4×	16	976
Mary K. McKenna United States	16	43 0.1×	321 1.0×	296 1.0×	586 2.2×	115 0.5×	30	857
Roopa Srinivasan United States	11	55 0.1×	384 1.2×	771 2.5×	399 1.5×	64 0.3×	17	1.0k
Mehmet Kemal Tur Germany	19	117 0.3×	627 2.0×	367 1.2×	267 1.0×	73 0.3×	43	1.1k
Michael Coon United States	11	26 0.1×	473 1.5×	423 1.4×	285 1.1×	210 0.9×	11	979

Countries citing papers authored by P. Urbas

Since Specialization

Citations

This map shows the geographic impact of P. Urbas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Urbas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Urbas more than expected).

Fields of papers citing papers by P. Urbas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Urbas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Urbas. The network helps show where P. Urbas may publish in the future.

Co-authorship network of co-authors of P. Urbas

This figure shows the co-authorship network connecting the top 25 collaborators of P. Urbas. A scholar is included among the top collaborators of P. Urbas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Urbas. P. Urbas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Algazi, Alain P., Jeffrey S. Weber, Stephanie Andrews, et al.. (2011). Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. British Journal of Cancer. 106(1). 85–91. 33 indexed citations

Daud, Adil, Christine Xu, Wen‐Jen Hwu, et al.. (2010). Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. Cancer Chemotherapy and Pharmacology. 67(3). 657–666. 17 indexed citations

DeConti, Ronald C., Alain P. Algazi, Stephanie Andrews, et al.. (2010). Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma. British Journal of Cancer. 103(10). 1548–1553. 12 indexed citations

Finkelstein, Steven E., Timothy S. Carey, Ingo Fricke, et al.. (2010). Changes in Dendritic Cell Phenotype After a New High-dose Weekly Schedule of Interleukin-2 Therapy for Kidney Cancer and Melanoma. Journal of Immunotherapy. 33(8). 817–827. 31 indexed citations

Algazi, Alain P., Jeffrey S. Weber, Stephanie Andrews, et al.. (2010). A phase I/II trial of DTIC and dasatinib in metastatic melanoma.. Journal of Clinical Oncology. 28(15_suppl). 8532–8532. 2 indexed citations

Daud, Adil, Jeffrey S. Weber, P. Urbas, et al.. (2009). Phase II trial of sagopilone (ZK-EPO), a novel synthetic epothilone, with significant activity in metastatic melanoma. Journal of Clinical Oncology. 27(15_suppl). 9031–9031. 6 indexed citations

Weber, Jeffrey S., Amod A. Sarnaik, Ş. Targan, et al.. (2009). Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multipeptide vaccine for resected stages IIIC and IV melanoma. Journal of Clinical Oncology. 27(15_suppl). 9023–9023. 8 indexed citations

Daud, Adil, Ronald C. DeConti, Stephanie Andrews, et al.. (2008). Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 26(36). 5896–5903. 503 indexed citations breakdown →

Daud, Adil, Noweeda Mirza, Brianna Lenox, et al.. (2008). Phenotypic and Functional Analysis of Dendritic Cells and Clinical Outcome in Patients With High-Risk Melanoma Treated With Adjuvant Granulocyte Macrophage Colony-Stimulating Factor. Journal of Clinical Oncology. 26(19). 3235–3241. 135 indexed citations

10.

DeConti, Ronald C., P. Urbas, Stephanie Andrews, et al.. (2008). Phase II trial of sagopilone (ZK-EPO), a novel epothilone, in patients with metastatic melanoma. Journal of Clinical Oncology. 26(15_suppl). 9046–9046. 8 indexed citations

11.

Heller, Richard, Jane L. Messina, Stephanie Andrews, et al.. (2006). 340 POSTER Gene therapy with plasmid IL-12 delivered by electroporation in patients with malignant melanoma: results of first human Phase I trial. European Journal of Cancer Supplements. 4(12). 106–106. 2 indexed citations

12.

Daud, Adil, Nikola Valkov, Barbara A. Centeno, et al.. (2005). Phase II Trial of Karenitecin in Patients with Malignant Melanoma: Clinical and Translational Study. Clinical Cancer Research. 11(8). 3009–3016. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact